Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EC-101
- Development stage
- Preclinical
- Lead developer
- ExoCan Healthcare Technologies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EC-101 is a preclinical-stage small molecule therapeutic being developed by ExoCan Healthcare Technologies for the treatment of oncology. ExoCan specializes in exosome-based technologies, and EC-101 is part of their "Exo-Inhibitor" program, which aims to disrupt the role of exosomes in cancer progression, metastasis, and drug resistance. By inhibiting the biogenesis, secretion, or uptake of tumor-derived exosomes, the drug is intended to modulate the tumor microenvironment and enhance the efficacy of existing therapies. The specific molecular target of EC-101 has not been publicly disclosed, but it is designed to target the exosome biogenesis pathway.
- Other names
- EC-101EC101EC 101
Beyond the preview
Go deeper on EC-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EC-101.